Paul Dagum, the Mindstrong Health CEO, argues that it is the time for mental disorder treatment to be approached through measurement of brain patterns. He further says that to treat mental illnesses effectively, the approach used to treat other chronic illnesses need to be adopted. He was speaking at a conference where Mindstrong Health announced that it had raised over $14 million to fund its new platform. See, http://www.massdevice.com/neuropsych-treatment-diagnosis-platform-dev-mindstrong-health-raises-14m-series/.
In a report by Market Wired, the platform that has been developed by Mindstrong health seeks to track a person’s brain-behavior as a result of how they handle their smartphone. It is argued that a person’s scrolling and typing pattern is directly linked to the brain functionality. This system will be able to tap a patient’s brain processing sequence, attention, and general function in a continuous & systematic method which can be analyzed. At the end, their true brain functionality and state will be established.
This new approach has been endorsed by renowned health practitioners like Jim Tananbaum, the CEO of Foresite Capital, which is among the companies funding this development. Other companies funding this new development include ARCH Venture Partners, Berggruen Holdings, the One Mind Brain Health Impact Fund, and Optum Ventures. These funding organizations all spoke well of this new development which is going to transform mental treatment.
About Jim Tananbaum
Jim Tananbaum is a healthcare entrepreneur who has been involved in the establishment and growth of many different pharmaceutical companies in his 25 years of working. According to ideamensch.com, he is currently the CEO of Foresite Capital which he founded and has seen it grow. Before Foresite Capital, Jim was involved in the development of GelTex Pharmaceuticals, Prospect Venture Partners II, and Theravance, Inc. He successfully led each of these companies to achieve great success. The experience he got from this companies pushed him to establish Foresite capital and to fund the development of other viable pharmaceutical companies.
Jim Tananbaum is a proud holder of an M.D and an M.B.A which he achieved from Harvard University. He also holds an M.s which he achieved at Massachusetts Institute of Technology and a B.S. and B.S.E.E he achieved at Yale University. This educational background is underlain by volunteer work at Yale University Advisory Board and Harvard-MIT HST as an advisor.